share_log

HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $36 Price Target

Benzinga ·  Sep 17 23:38  · Ratings

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $36 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment